Print Version
MMWR: Updated Guidelines for the Use of Rifabutin or Rifampin for the Treatment and Prevention of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors
Author:
Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, Office of the Morbidity and Mortality Weekly Report Series, CDC MMWR
Publication Date:
2000
Country of Origin:
United States
Format:
Guideline
Language:
English
Abstract
This guideline presents updated data about drug interactions between protease inhibitors and non-nucleoside reverse transcriptase inhibitors for treatment of HIV infection together with rifamycins for treatment of TB.Publisher:
Centers for Disease Control and Prevention (CDC)
Topic:
Case Management, Treatment Guidelines Materials, HIV Co-infection, Treatment- TB Disease, TB Treatment, Treatment- Medication Information
Notes:
CDC National Center for HIV, STD, and TB Prevention (NCHSTP): Materials can be ordered in a number of ways: 1) By accessing the online order form at www.cdc.gov/nchstp/tb; 2) by faxing a request for material to the NCHSTP Office of Communications at 404-639-8910; or 3) by mailing a request to the CDC NCHSTP Office of Communications at 1600 Clifton Rd, NE, MS E-07, Atlanta GA 30333. Request item #99-6422.
Massachusetts Medical Society: paper copies of single issues cost $5.25.
Disclaimer: The information on the Find TB Resources Website is made available as a public service. Neither the Centers for Disease Control and Prevention nor the National Prevention Information Network endorses the organizations, Website s, and materials presented. It is the responsibility of the user to evaluate this information prior to use based on individual, community, and organizational needs and standards.